Mirati Therapeutics shares are trading higher amid an FDA advisory committee meeting discussing a rival drug by Amgen.
Portfolio Pulse from Benzinga Newsdesk
Mirati Therapeutics shares are trading higher amid an FDA advisory committee meeting discussing a rival drug by Amgen.
October 05, 2023 | 6:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirati Therapeutics shares are trading higher due to an FDA advisory committee meeting discussing a rival drug by Amgen.
The FDA's discussion of a rival drug by Amgen could potentially impact the competitive landscape for Mirati Therapeutics. This has led to increased trading and a rise in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100